सभी अध्ययन
पूर्णचरण IIIहस्तक्षेपात्मक

An open-label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets

Primary sclerosing cholangitis (PSC) is a rare condition that causes swelling and scarring in the liver's bile ducts. This phase 3 study, named NUT-022/PSC, offers ongoing treatment to adults who previously finished or took part in an earlier trial called NUC-5/PSC. Participants will take three tablets of norucholic acid (1500 mg total) each day. This replaces the six capsules taken in the previous trial, making the daily dose easier to take. Because this is an 'open-label' study, there is no dummy pill (placebo); every person receives the active medicine. The main aim is to understand how well norucholic acid works and how safe it is over a longer period of up to four years. Researchers will monitor liver health through regular blood tests and painless ultrasound scans at hospital visits every three months.

एक नजर में

स्थिति
पूर्ण
चरण
चरण III
प्रायोजक
Dr Falk Pharma (Germany)
नामांकन लक्ष्य
125
प्रारंभ
31 मार्च 2025
अनुमानित पूर्णता
09 Apr 2026

यह अध्ययन किस बारे में है?

Primary sclerosing cholangitis (PSC) is a long-term liver disease where the bile ducts—the tiny tubes carrying digestive juices out of the liver—become inflamed and scarred. Over time, this can lead to bile build-up and liver damage. Finding treatments that can safely protect the liver over many years is an urgent goal for doctors and researchers.

This trial builds directly on an earlier study known as NUC-5/PSC. Researchers have developed a new tablet form of a medicine called norucholic acid (NCA). In earlier stages, participants took six capsules every day. The new tablets provide the exact same daily dose in just three tablets, which aims to make taking the treatment simpler and more convenient.

Because this is an 'open-label' study, you and your medical team will both know that you are taking the real study drug. No one will receive a dummy pill (placebo). The results will help doctors understand whether norucholic acid can safely improve liver health over a prolonged period and support its possible approval as a future treatment for PSC.

मुख्य निष्कर्ष

  • This study is open only to people who took part in the previous NUC-5/PSC trial.
  • All participants receive the active medicine (norucholic acid); there is no placebo.
  • The daily treatment involves three tablets instead of the previous six capsules.
  • Participation lasts up to four years, with check-ups every three months.
  • Joining is voluntary, and you can withdraw at any time without losing your usual care.

कौन पात्र हो सकता है?

To join this study, you must be 18 years of age or older and have a confirmed diagnosis of primary sclerosing cholangitis (PSC). Crucially, you must have already taken part in the earlier NUC-5/PSC clinical trial.

If you take ursodeoxycholic acid (UDCA), a common medicine used for liver bile conditions, your daily dose must be within an approved limit and kept steady.

Women who can become pregnant must agree to use reliable, highly effective birth control throughout the trial and for four weeks after their last dose. Your study doctor will discuss suitable options with you to ensure your safety.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. I am aged 18 or older.
  2. I have a confirmed diagnosis of primary sclerosing cholangitis (PSC).
  3. I previously took part in the NUC-5/PSC study.
  4. If female and able to have children, I am willing to use reliable contraception.
  5. If taking ursodeoxycholic acid (UDCA), my daily dose is stable and not above 20 mg/kg.
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to join, you will take three norucholic acid tablets once a day by mouth, giving you a total dose of 1500 mg. The study can last for up to 216 weeks (around four years). During this time, you will visit the hospital roughly once every three months, totalling around 20 visits. Most check-ups include routine physical exams and small blood tests (around 30 ml, or two tablespoons). At weeks 72 and 144, you will have more comprehensive health reviews, which include quick, non-invasive imaging tests such as an ultrasound to check the stiffness of your liver. Five hospital centres across the UK are taking part.

संभावित जोखिम और लाभ

You might experience improvements in your liver condition, but direct health benefits cannot be promised, and your PSC could stay the same or worsen. However, your participation will provide valuable scientific knowledge to help future PSC patients. The medicine may cause unwanted side effects or allergic reactions, which your study doctor will closely manage. Having blood taken can cause minor bruising, discomfort, or rarely, slight inflammation or nerve irritation around the vein. Taking part is completely your choice, and you are free to leave the trial at any time without this affecting your everyday medical care.

स्थान (5)

  • Norfolk and Norwich University Hospital
    अनुमानित
    Norwich, England
  • यूनिवर्सिटी हॉस्पिटल्स बर्मिंघम एनएचएस फाउंडेशन ट्रस्ट
    केवल शहर
    Birmingham, England
  • Royal Free London NHS Foundation Trust
    केवल शहर
    लंदन, इंग्लैंड
  • Kings College Hospital
    अनुमानित
    लंदन, इंग्लैंड
  • Freeman Hospital
    अनुमानित
    न्यूकैसल अपॉन टाइन, इंग्लैंड

सामान्य प्रश्न

Will I receive a dummy treatment (placebo)?

No. This is an open-label study, meaning every participant receives the real norucholic acid tablets.

How are these tablets different from the medicine in the last study?

The medicine itself is the same, but it is now pressed into tablets so you only need to take three tablets a day instead of six capsules.

How often do I need to attend the clinic?

You will have regular follow-up visits every three months, with around 20 hospital visits planned across four years.

Can I continue taking my other liver medicines?

Yes, common medicines like ursodeoxycholic acid (UDCA) are generally allowed, provided your dose remains stable and within trial guidelines.

What happens if I change my mind about taking part?

You can leave the study at any point without giving a reason. Your standard NHS care will continue as normal.

और अधिक जानने के लिए कैसे पता करें

Clara Grundmann

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.